Adam Bartnik

Adam Bartnik currently serves as the Chief Financial Officer at Reprieve Cardiovascular and Principal Consultant at Ascend Bio Advisors LLC. Previously, Adam held the position of Vice President of R&D Finance at Vertex Pharmaceuticals, where responsibilities included leading the R&D FP&A group and supporting executive leadership with strategic planning, budget management, and financial health reporting for a $2.5 billion operating expense. Adam's extensive career at Bristol-Myers Squibb spanned various leadership roles, including Vice President of Corporate Financial Planning & Analysis and Executive Director of Finance for R&D Portfolio Management and Analysis, overseeing budgets, forecasts, and long-term strategy. Early experience includes positions at TMF Group, focusing on establishing foreign companies in Poland. Adam Bartnik holds a Master’s degree in Economics from Uniwersytet Marii Curie-Skłodowskiej w Lublinie.